Research Analysts Issue Forecasts for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - HC Wainwright cut their FY2025 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research note issued to investors on Monday, April 7th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.47) for the year, down from their previous estimate of ($0.33). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share.

CRDL has been the subject of several other research reports. RODMAN&RENSHAW upgraded Cardiol Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of Cardiol Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $7.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $8.40.

Cardiol Therapeutics Price Performance

NASDAQ:CRDL traded up $0.02 during mid-day trading on Thursday, hitting $1.05. The company's stock had a trading volume of 119,119 shares, compared to its average volume of 383,252. Cardiol Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $3.12. The company has a market capitalization of $86.99 million, a price-to-earnings ratio of -2.70 and a beta of 1.00. The stock has a fifty day moving average of $1.10 and a 200-day moving average of $1.41. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01.

Hedge Funds Weigh In On Cardiol Therapeutics

Institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp bought a new position in Cardiol Therapeutics during the 4th quarter worth approximately $25,000. Jane Street Group LLC bought a new position in shares of Cardiol Therapeutics during the third quarter worth $29,000. Cetera Investment Advisers acquired a new position in shares of Cardiol Therapeutics in the 4th quarter valued at $56,000. Virtu Financial LLC bought a new stake in shares of Cardiol Therapeutics in the 4th quarter valued at $61,000. Finally, Atria Investments Inc acquired a new stake in Cardiol Therapeutics during the 4th quarter worth $174,000. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.